Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

FDA Approves OptiClik(TM), New Insulin Pen System from Aventis

Posted: Thursday, August 19, 2004

“The OptiClik(TM) pen will provide people with diabetes with a new and easy-to-use delivery option, one that will complement Lantus(R), the first and only 24-hour basal insulin analog,” said Kim Carroll, Vice President, Diabetes at Aventis.

 

"With the approval of OptiClik(TM), Aventis furthers its goal of offering people with diabetes an integrated system of insulin products and choice of delivery devices to achieve precision dosing and meet their needs for blood glucose control," adds John Harrington, Vice President Metabolism Business Unit at Aventis. Insiders report that Aventis will be offering their new fast acting Insulin, Apidra, in the same pen.

 

 

Source: Diabetes In Control.com.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.